Mepolizumab Medicine 09 January 2018 Extended indication COPD Therapeutic value No judgement Total cost € 1,971,022,500.00 Registration phase Unknown Product Active substance Mepolizumab Domain Lung diseases Reason of inclusion Main indication COPD Extended indication COPD Current proprietary name Already available biosimilars / generics Proprietary name Nucala Manufacturer GSK Portfolio holder Mechanism of action Unknown Route of administration Subcutaneous Therapeutical formulation Injection Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Al geregistreerd voor astma. Registration Registration route Centralised (EMA) Type of trajectory Unknown Particularity Unknown ATMP Unknown Submission date Expected Registration 2018 Orphan drug No Registration phase Unknown Reimbursement Medicine sluice Additional remarks Indicatie-uitbreiding Therapeutic value Current treatment options Therapeutic value No judgement This assessment does not indicate any potential inclusion in the package. Substantiation Wordt off-label al voorgeschreven. Duration of treatment Frequency of administration 1 times a month Dosage per administration 100 mg References Additional remarks Expected patient volume per year Patient volume 5,000 - 250,000 Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost € < 15,459.00 This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year. References Medicijnkosten.nl Additional remarks Meerkosten. per injectieflacon van 100mg fl € 1263,52. Komt bovenop huidige kosten. Potential total cost per year Total cost € 1,971,022,500.00 Total cost for sluice Additional remarks Off label use Off label use Yes Indications off label use References Additional remarks Indication extension Indication extensions Yes Indication extensions Meerdere fase 3 studies References Additional remarks Other information Additional remarks